Novo Nordisk A/S NVO reported first-quarter 2025 earnings of 92 cents per American Depositary Receipt (ADR), which matched ...

Bangkok, Thailand – 6 May 2025 – Novo Nordisk Pharma (Thailand ... also carry a powerful message—equitable access to quality products with a contribution to society. Nanyang has been ...

Novo Nordisk NVO is expected to beat estimates when it reports its first-quarter 2025 results before the opening bell on May ...

In a unique collaboration to raise awareness of haemophilia in Thailand, Danish healthcare company Novo Nordisk and Thai ...

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in ... in protein therapies for hemophilia and other disorders.

Hemophilia B products’ sales increased 27%. Sales of NovoSeven decline 5% to DKK 1.9 billion. Sales of Novo Nordisk’s rare endocrine disorder products jumped 14% to DKK 1.3 billion.

Novo Nordisk’s revenues under the Rare Disease segment are expected to have increased in the to-be-reported quarter, mainly due to higher sales of its hemophilia A and B products. Year to date ...